To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you.
X

Privacy Policy Update

We remain dedicated to protecting your data and experience throughout our platforms. We have updated our Privacy Policy and your continued use of the Site means you have accepted the revised Privacy Policy. View now >
X
Search

NK-92® (ATCC® CRL-2407™)

Organism: Homo sapiens, human  /  Cell Type: natural killer cell; NK cell  /  Tissue: peripheral blood  /  Disease: malignant non-Hodgkin's lymphoma

Permits and Restrictions

View Permits View Restrictions
Organism Homo sapiens, human
Tissue peripheral blood
Cell Type natural killer cell; NK cell
Product Format frozen
Morphology lymphoblast
Culture Properties suspension, multicell aggregates
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease malignant non-Hodgkin's lymphoma
Age 50 years
Gender male
Ethnicity Caucasian
Applications
This cell line is a suitable transfection host.

The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays.

NK-92® cells (after irradiation to prevent proliferation) can be used effectively for immunological ex vivo purging of leukemia from blood without compromising hematopoietic cell function.
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
NK-92® is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma.
Clinical Data
50 years
Caucasian, White
male
Antigen Expression
CD2 +, CD7 +, CD11a +, CD28 + , CD45 +, CD54 +, CD56 +, CD1 -, CD3 -, CD4 -, CD5 -, CD8 -, CD10 -, CD14 -, CD16 -, CD19 -, CD20 -, CD23 -, CD34 -, HLA-DR -
Comments
The cell line is dependent on the presence of recombinant Il-2 and a dose as low as 10 U/mL is sufficient to maintain proliferation; cells will die within 72 hours in the absence of IL-2.

NK-92® cells have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR.

ATCC confirmed this cell line is positive for the presence of Epstein-Barr viral DNA sequences via PCR.
Complete Growth Medium The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; 100-200 U/ml recombinant IL-2; adjust to a final concentration of 12.5% horse serum and 12.5% fetal bovine serum.
Subculturing

Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 2 to 3 X 105 viable cells/mL. These cells tend to grow in aggregates that may lose viability when they are dispersed. Accurate counts and viabilities may not be possible. Corning® T-75 flasks (catalog #431464) are recommended for subculturing this product.

NK-92® cells are extremely sensitive to overgrowth and media exhaustion.
Medium Renewal: Replace with fresh medium every 2 to 3 days (depending on cell density)
Note: Successful growth of this cell line is very dependent upon the quality of IL-2 used in the growth medium. ATCC recommends using the highest quality IL-2 available.
Cryopreservation
Freeze medium: 50% FBS; 40% complete growth medium ; 10% DMSO.
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile
Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 9,12
D16S539: 11,12
D5S818: 12,13
D7S820: 10,11
TH01: 6,9.3
TPOX: 8
vWA: 18
Name of Depositor NantKwest Inc.
Deposited As human
References

Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260

Klingemann HG, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301

Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666

Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869

Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151

Yan Y, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753

Maki G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501

Nagashima S, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023

Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • For-profit customers must obtain a research use license agreement from the Contributor prior to shipment.
  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Other Documentation
Other Document
Cell Micrograph
FAQ's
  1. Growth medium for NK-92® (ATCC® CRL-2407™)
    To prepare the recommended medium for
    Date Updated: 2/4/2020
Restrictions

The NK-92® cell line was deposited at the ATCC by NantKwest Inc. and is available with the following restrictions:

  1. Not-for-profit academic institutions may use this cell line for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes, including but not limited to the testing or validation of any commercial product or instrument. Nor can the cells be distributed to third parties for any reason, including purposes of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied.
  2. For-profit commercial organizations must obtain a research use and/or a commercial license directly from NantKwest Inc. For instructions on how to proceed, please contact NantKwest’s licensing department via email at contact@nantkwest.com.
References

Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260

Klingemann HG, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301

Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666

Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869

Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151

Yan Y, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753

Maki G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501

Nagashima S, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023

Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052